Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer

Overview of attention for article published in Frontiers in Pharmacology, October 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 2 X users

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,047 followers.

RT @FrontPharmacol: New Research: Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic naso…

30 Oct 2023

Reply Repost Favourite

New Research: Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer https://t.co/PEz4yNxLhy #pharmacology

30 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.